This press release contains forward-looking statements. These statements are based on management`s current expectations and currently available information, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those set forth in this press release. Forward-looking statements are subject to future events, risks, uncertainties and other factors that may result in actual results differing materially from those anticipated by the statements, including, but not limited to, the ability to enter into new contracts, maintain customer relationships, to manage the opening of new offices and the provision of new services, to integrate new mergers and acquisitions. n companies, as well as economic and global market conditions and other risks and uncertainties identified from time to time in the SEC reports presented by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, do not rely too much on these forward-looking statements to make investment decisions. The word “expected” and variations of such words and similar phrases are intended to identify forward-looking statements. Forward-looking statements speak only as of the time they are made and we do not undertake to publicly update any forward-looking statements, whether as a result of new information, future events or other reasons. For more information about the risks and uncertainties associated with these forward-looking statements, please refer to the SEC`s reports presented by ICON, including Forms 20-F, F-1, S-8 and F-3 available on the SEC`s website under www.sec.gov. The agreement builds on the existing relationship of the companies in which ICON provides global expertise in the planning, conduct, management and conduct of clinical trials. Dublin, Ireland, 3. April 2020 – ICON plc, (NASDAQ: ICLR), a global leader in drug and equipment development and commercialization services for the pharmaceutical, biotechnology and medical industries, today announced that it has signed a three-year agreement with Pfizer Inc.
(NYSE:PFE). Under the terms of the agreement, Pfizer has the right to extend the term for up to two additional years. Financial details of the deal were not disclosed. ICON plc is a global provider of outsourced drug and equipment development and commercialization services for pharmaceutical, biotechnology, medical device, government and healthcare organizations. The company specializes in the strategic development, management and analysis of programs that support clinical development, from the selection of active substances to Phase I-IV clinical trials. . . .